Epigenetic Alterations in Alzheimer's Disease: Impact on Insulin Signaling and Advanced Drug Delivery Systems

Alosh Greeny,Ayushi Nair,Prashant Sadanandan,Sairaj Satarker,Ademola C. Famurewa,Madhavan Nampoothiri

DOI: https://doi.org/10.3390/biology13030157

2024-02-29

Biology

Abstract:Alzheimer's disease (AD) is a neurodegenerative condition that predominantly affects the hippocampus and the entorhinal complex, leading to memory lapse and cognitive impairment. This can have a negative impact on an individual's behavior, speech, and ability to navigate their surroundings. AD is one of the principal causes of dementia. One of the most accepted theories in AD, the amyloid β (Aβ) hypothesis, assumes that the buildup of the peptide Aβ is the root cause of AD. Impaired insulin signaling in the periphery and central nervous system has been considered to have an effect on the pathophysiology of AD. Further, researchers have shifted their focus to epigenetic mechanisms that are responsible for dysregulating major biochemical pathways and intracellular signaling processes responsible for directly or indirectly causing AD. The prime epigenetic mechanisms encompass DNA methylation, histone modifications, and non-coding RNA, and are majorly responsible for impairing insulin signaling both centrally and peripherally, thus leading to AD. In this review, we provide insights into the major epigenetic mechanisms involved in causing AD, such as DNA methylation and histone deacetylation. We decipher how the mechanisms alter peripheral insulin signaling and brain insulin signaling, leading to AD pathophysiology. In addition, this review also discusses the need for newer drug delivery systems for the targeted delivery of epigenetic drugs and explores targeted drug delivery systems such as nanoparticles, vesicular systems, networks, and other nano formulations in AD. Further, this review also sheds light on the future approaches used for epigenetic drug delivery.

biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the impact of epigenetic changes in Alzheimer's Disease (AD) on insulin signaling and its relationship with advanced drug delivery systems. Specifically, the article focuses on the following points:

1. **Epigenetic changes**: The paper discusses in detail how epigenetic mechanisms such as DNA methylation and histone modifications affect gene expression, especially in genes related to insulin resistance. These epigenetic changes not only occur in peripheral tissues but also lead to impaired insulin signaling in the brain, thus promoting the development of AD.

2. **Insulin signaling**: The article emphasizes the importance of insulin signaling in the pathogenesis of AD. Insulin not only plays a crucial role in regulating blood - glucose levels but also has an important role in neuroprotection and synaptic plasticity. Research has found that impaired insulin signaling may be an important pathological feature of AD.

3. **Advanced drug delivery systems**: In order to effectively treat AD, new drug delivery systems that can target the brain need to be developed. The paper discusses several advanced drug delivery systems, such as nanoparticles, vesicular systems, network systems, dendrimers, hydrogel - based systems and biologics, which can improve the targeting and efficacy of drugs.

In summary, the main purpose of this paper is to provide new ideas and methods for the treatment of AD by exploring the impact of epigenetic changes on insulin signaling and how these changes lead to the occurrence and development of AD. At the same time, the paper also discusses how to use advanced drug delivery systems to improve the treatment effect of AD.